Abstract
Wastewater-based surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is used to monitor the population-level prevalence of the COVID-19 disease. In many cases, due to lockdowns or analytical delays, the analysis of wastewater samples might only be possible after prolonged storage. In this study, the effect of storage conditions on the RNA copy numbers of the SARS-CoV-2 virus in wastewater influent was studied over time at cold storage temperatures using the reverse-transcription quantitative PCR (RT-qPCR) assays N2 and E-Sarbeco. For the first time in Finland, quantifiable numbers of SARS-CoV-2 RNA copies were detected in 24 h composite incoming wastewater samples collected from Viikinmäki wastewater treatment plant, Helsinki, Finland. The SARS-CoV-2 RNA counts of the wastewater sample aliquots taken during 19–20 April 2020 and stored for 29, 64, and 84 days remained surprisingly stable at 4°C, -20°C, and -75°C. The SARS-CoV-2 copy numbers in the stored samples seemed slightly higher when analyzed from the pre-centrifugation pellet—that is, the particulate matter of the influent—as compared with the supernatant (i.e., water fraction) used for ultrafiltration, although the difference was not statistically significant. With an N2 assay, on average the sample aliquots contained 3.3 ± 0.18 and 2.9 ± 0.06 SARS-CoV-2 RNA copies (log10 ± SE 100 ml-1) in a pre-centrifugation pellet and supernatant ultrafiltrated, respectively. The corresponding numbers with an E-Sarbeco assay were 3.2 ± 0.24 in the pellet and 2.8 ± 0.12 in supernatant. Furthermore, when wastewater was spiked with SARS-CoV-2, linear decay at 4°C was observed on the first 28 days, while no decay was visible within 58 days at -20°C or -75°C. In conclusion, freezing temperatures should be used for storage when immediate SARS-CoV-2 analysis from the wastewater influent is not possible. Analysis of the particulate matter of the sample, in addition to the water fraction, can improve the detection frequency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Finnish Government supplementary budget for Covid-19 research and the Ministry of Agriculture and Forestry (grant number 4400T-0807).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Finnish Institute for Health and Welfare.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available within the article.
